BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

Search

Sanofi SA

Avatud

SektorTervishoid

92.72 -0.67

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

92.27

Max

94.26

Põhinäitajad

By Trading Economics

Sissetulek

-2.3B

499M

Müük

-6.5B

7.6B

P/E

Sektori keskmine

20.663

57.333

Aktsiakasum

1.31

Dividenditootlus

4.32

Kasumimarginaal

6.539

Töötajad

82,878

EBITDA

-3.7B

563M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+22.28% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

4.32%

2.63%

Turustatistika

By TradingEconomics

Turukapital

-20B

111B

Eelmine avamishind

93.39

Eelmine sulgemishind

92.72

Tehniline skoor

By Trading Central

Kindlus

Neutral Evidence

Sanofi SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. apr 2025, 08:52 UTC

Tulu

Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug -- Update

24. apr 2025, 05:44 UTC

Tulu

Sanofi Sales, Profit Beat Expectations

9. apr 2025, 06:00 UTC

Omandamised, ülevõtmised, äriostud

Santander Exploring Options to Sell Polish Unit Stake, Bloomberg Says, Citing Sources

20. märts 2025, 06:43 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

24. apr 2025, 12:54 UTC

Market Talk
Tulu

Sanofi's Pipeline Updates Seem Mixed -- Market Talk

24. apr 2025, 10:06 UTC

Market Talk
Tulu

Sanofi Starts the Year Strong -- Market Talk

10. apr 2025, 12:06 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

PKO's Hypothetical Acquisition of Santander's Polish Unit Could Increase Its Role in Sector -- Market Talk

10. apr 2025, 09:10 UTC

Kuumad aktsiad

Stocks to Watch Thursday: Trump Media, U.S. Steel, Tesla, Barclays -- WSJ

9. apr 2025, 10:49 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Erste Bank Seen as Potential Buyer for Santander's Polish Unit -- Market Talk

9. apr 2025, 08:19 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Capital Deployment From Santander's Potential Poland Disposal Is Key Question -- Market Talk

9. apr 2025, 06:59 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Potential Santander Polish Exit Less Compelling Than Sale of U.K. Bank -- Market Talk

9. apr 2025, 06:46 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Santander's Potential Polish Operations Disposal Could Free Up Capital to Boost Returns Elsewhere -- Market Talk

4. apr 2025, 09:07 UTC

Kuumad aktsiad

Stocks to Watch Friday: Glencore, Apple, Barclays -- WSJ

3. apr 2025, 07:51 UTC

Market Talk

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

2. apr 2025, 13:44 UTC

Market Talk

Santander Push Into Canada on the Cards -- Market Talk

2. apr 2025, 09:27 UTC

Kuumad aktsiad

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

26. märts 2025, 06:19 UTC

Market Talk
Tulu

Santander Surpasses 100 Billion-Euro Valuation Milestone -- Market Talk

25. märts 2025, 10:08 UTC

Market Talk

Santander Needs Step-Up in Profitability to Fully Close Discount -- Market Talk

20. märts 2025, 09:00 UTC

Peamised uudised

'Anti-Woke' in the U.S., DEI at Home: the New Playbook for European Companies -- WSJ

20. märts 2025, 06:05 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: Deal Seeks to Broaden Immunology Pipeline

20. märts 2025, 06:05 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

20. märts 2025, 06:04 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Pay $600M Upfront

20. märts 2025, 06:02 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

20. märts 2025, 06:00 UTC

Omandamised, ülevõtmised, äriostud

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

18. märts 2025, 09:33 UTC

Kuumad aktsiad

Stocks to Watch Tuesday: Nvidia, BYD, Santander, Google -- WSJ

17. märts 2025, 23:00 UTC

Peamised uudised

Santander Pushes to Expand U.S. Operations by Utilizing Verizon Customer Base -- WSJ

13. märts 2025, 09:50 UTC

Tulu

Santander Approves Final Cash Dividend Per Share of EUR11 cents

13. märts 2025, 09:49 UTC

Tulu

Santander Increased 2024 Cash Payments by 19%

24. veebr 2025, 08:56 UTC

Market Talk
Tulu

European Banks' Quarterly Beats Confirm Momentum -- Market Talk

24. veebr 2025, 08:30 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Southern European Banks' Strong Finish to 2024 Confirms Attractiveness -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Sanofi SA Prognoos

Hinnasiht

By TipRanks

22.28% tõus

12 kuu keskmine prognoos

Keskmine 114.144 EUR  22.28%

Kõrge 127 EUR

Madal 83.729 EUR

Põhineb 14 Wall Streeti analüütiku instrumendi Sanofi SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

14 ratings

10

Osta

4

Hoia

0

Müü

Tehniline skoor

By Trading Central

91.62 / 93.4Toetus ja vastupanu

Lühikene perspektiiv

Neutral Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Strong Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.